Eli Lilly soldiers on in big PhIII evacetrapib study

Eli Lilly ($LLY) says that it will push ahead to the end on its Phase III study of evacetrapib, a CETP inhibitor that hopes to succeed where other giants have failed. Lilly says that the ACCELERATE study data monitoring committee recommended continuing the study following a futility analysis. The last patient visit in the study is expected in July of 2016. Investigators recruited roughly 12,000 patients for this trial. Release